doxapram has been researched along with Neoplasms, Bronchial in 1 studies
Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Laxenaire, MC | 1 |
Boileau, S | 1 |
Dagrenat, P | 1 |
Menu, N | 1 |
Drouet, N | 1 |
1 trial available for doxapram and Neoplasms, Bronchial
Article | Year |
---|---|
Haemodynamic and respiratory effects of post-operative doxapram and almitrine in patients following pneumonectomy.
Topics: Almitrine; Blood Pressure; Bronchial Neoplasms; Doxapram; Hemodynamics; Humans; Male; Myocardial Con | 1986 |